283 related articles for article (PubMed ID: 35019724)
1. Reduction of CD8 T Cell Functionality but Not Inhibitory Capacity by Integrase Inhibitors.
Richter E; Bornemann L; Korencak M; Alter G; Schuster M; Esser S; Boesecke C; Rockstroh J; Gunzer M; Streeck H
J Virol; 2022 Mar; 96(5):e0173021. PubMed ID: 35019724
[TBL] [Abstract][Full Text] [Related]
2. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
[TBL] [Abstract][Full Text] [Related]
3. CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study.
Sangaré MN; Baril JG; de Pokomandy A; Klein M; Thomas R; Tremblay C; Pexos C; Durand M; Chawla S; Laporte L; Trottier H
Clin Infect Dis; 2023 Jun; 76(11):1879-1888. PubMed ID: 36722329
[TBL] [Abstract][Full Text] [Related]
4. Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study.
Masiá M; Padilla S; Barber X; Sanchis M; Terol G; Lidón F; Gutiérrez F
Medicine (Baltimore); 2016 Mar; 95(11):e3108. PubMed ID: 26986155
[TBL] [Abstract][Full Text] [Related]
5. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study.
Serrano-Villar S; Martínez-Sanz J; Ron R; Talavera-Rodríguez A; Fernández-Felix BM; Herrera S; Muriel A; Fanjul F; Portilla J; Muñoz J; Amador C; de Zárraga MA; Vivancos MJ; Moreno S;
Lancet HIV; 2020 Aug; 7(8):e565-e573. PubMed ID: 32763219
[TBL] [Abstract][Full Text] [Related]
6. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
Hu Z; Kuritzkes DR
J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
[TBL] [Abstract][Full Text] [Related]
7. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.
Bourgi K; Rebeiro PF; Turner M; Castilho JL; Hulgan T; Raffanti SP; Koethe JR; Sterling TR
Clin Infect Dis; 2020 Mar; 70(7):1267-1274. PubMed ID: 31100116
[TBL] [Abstract][Full Text] [Related]
8. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
[TBL] [Abstract][Full Text] [Related]
9. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L
HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978
[TBL] [Abstract][Full Text] [Related]
10. Integrase Strand Transfer Inhibitor Start or Switch Impacts Learning in Women With HIV.
O'Halloran JA; Wang K; Spence AB; Williams DW; Dastgheyb R; Fitzgerald KC; Kamkwalala AR; Maki PM; Sharma A; Gustafson DR; Milam J; Weber KM; Adimora AA; Ofotokun I; Fischl MA; Konkle-Parker D; Lahiri CD; Sheth AN; Xu Y; Rubin LH
J Acquir Immune Defic Syndr; 2021 Apr; 86(5):593-599. PubMed ID: 33394812
[TBL] [Abstract][Full Text] [Related]
11. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD;
Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454
[TBL] [Abstract][Full Text] [Related]
12. Rapid Initiation of Antiretroviral Therapy Following Diagnosis of Human Immunodeficiency Virus Among Patients with Commercial Insurance Coverage.
Benson C; Emond B; Lefebvre P; Lafeuille MH; Côté-Sergent A; Tandon N; Chow W; Dunn K
J Manag Care Spec Pharm; 2020 Feb; 26(2):129-141. PubMed ID: 31747358
[TBL] [Abstract][Full Text] [Related]
13. Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy.
Fabbiani M; Borghetti A; Squillace N; Colafigli M; Taramasso L; Lombardi A; Rossetti B; Ciccullo A; Colella E; Picarelli C; Berruti M; Latini A; Montagnani F; Sambo M; Di Biagio A; Gori A; Di Giambenedetto S; Bandera A
J Acquir Immune Defic Syndr; 2021 Jan; 86(1):119-127. PubMed ID: 33306566
[TBL] [Abstract][Full Text] [Related]
14. Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study.
Trickey A; Zhang L; Gill MJ; Bonnet F; Burkholder G; Castagna A; Cavassini M; Cichon P; Crane H; Domingo P; Grabar S; Guest J; Obel N; Psichogiou M; Rava M; Reiss P; Rentsch CT; Riera M; Schuettfort G; Silverberg MJ; Smith C; Stecher M; Sterling TR; Ingle SM; Sabin CA; Sterne JAC
Lancet HIV; 2022 Jun; 9(6):e404-e413. PubMed ID: 35659335
[TBL] [Abstract][Full Text] [Related]
15. Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens.
Gianotti N; Muccini C; Galli L; Poli A; Spagnuolo V; Andolina A; Galizzi N; Ripa M; Messina E; Piatti PM; Lazzarin A; Castagna A
J Med Virol; 2019 Nov; 91(11):1937-1943. PubMed ID: 31286527
[TBL] [Abstract][Full Text] [Related]
16. Emergent drug resistance with integrase strand transfer inhibitor-based regimens.
Lepik KJ; Harrigan PR; Yip B; Wang L; Robbins MA; Zhang WW; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
AIDS; 2017 Jun; 31(10):1425-1434. PubMed ID: 28375875
[TBL] [Abstract][Full Text] [Related]
17. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents.
The RESPOND Study Group
AIDS; 2021 May; 35(6):869-882. PubMed ID: 33443370
[TBL] [Abstract][Full Text] [Related]
18. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
[TBL] [Abstract][Full Text] [Related]
19. Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.
Kagan RM; Dunn KJ; Snell GP; Nettles RE; Kaufman HW
AIDS Res Hum Retroviruses; 2019 Aug; 35(8):698-709. PubMed ID: 31169022
[TBL] [Abstract][Full Text] [Related]
20. Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naïve and Experienced Individuals from Western India.
Karade S; Sen S; Sashindran VK
AIDS Res Hum Retroviruses; 2019 Jun; 35(6):567-571. PubMed ID: 30793915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]